Related Experiment Video

Updated: Jul 19, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K

One-Year follow-up of 50 Rural Underprivileged Type 1 Diabetes Children on Insulin Pump Therapy: Breaking

Krishnan Swaminathan1

  • 1Consultant Endocrinologist, Madhuram Diabetes and Thyroid Centre, Coimbatore, Tamil Nadu, India.

Indian Journal of Endocrinology and Metabolism
|August 16, 2023
PubMed

Insights

Insulin pump therapy improved clinical outcomes for underprivileged children with Type 1 diabetes, reducing hospital admissions. Partnerships are key to expanding access to this technology for vulnerable populations.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Technology
  • Public Health

Background:

  • Type 1 diabetes affects underprivileged children, often with limited access to advanced care.
  • Traditional multiple daily injection (MDI) therapy can be challenging for managing pediatric diabetes.
  • Rural populations face unique barriers to consistent diabetes management and technology adoption.

Purpose of the Study:

  • To evaluate the feasibility and clinical outcomes of insulin pump therapy in rural, underprivileged children with Type 1 diabetes.
  • To assess the one-year effectiveness of insulin pump therapy compared to MDI in this specific demographic.
  • To identify barriers and facilitators for implementing diabetes technology in low-income settings.

Main Methods:

  • A prospective audit of fifty rural underprivileged children with Type 1 diabetes was conducted.
  • Patients served as their own controls, transitioning from MDI to insulin pump therapy.
  • Data were collected from a specialized diabetes center database and analyzed over a one-year period.

Main Results:

  • Significant reductions in glycosylated hemoglobin (HbA1c) were observed at 6 months and one year post-pump initiation.
  • Insulin pump therapy led to a significant decrease in hospital admissions for diabetic ketoacidosis.
  • There was a notable reduction in admissions due to severe hypoglycemia among participants.

Conclusions:

  • Insulin pump therapy is a feasible and clinically beneficial option for well-selected, underprivileged children with Type 1 diabetes.
  • Collaborative efforts between non-governmental organizations (NGOs), private sectors, and industry are crucial for broader access to diabetes technologies.
  • Improving access to insulin pump therapy can lead to meaningful clinical improvements in vulnerable pediatric populations.
Abstract

Keywords:
Insulin pumpPoor socio-economic strataType 1 diabetes

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.4K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.1K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
207
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
226
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
311